The CCl4-induced liver fibrosis model is a widely used model for evaluating the efficacy of drugs against cirrhosis. Unlike our STAM™ model, it shows a bridging fibrosis pattern and develops severe fibrosis. The test period can be as short as four weeks, and is also suitable for simple screening of test substances for efficacy against fibrosis. We offer Valsartan as a positive control for this model. Utilizing the expertise obtained by evaluating the pathological tissues from various fibrosis models, we are able to extract the medical efficacy of your compound to the fullest extent.